BRAF mutation testing in clinical practice

J Ziai, P Hui - Expert review of molecular diagnostics, 2012 - Taylor & Francis
Serine/threonine-protein kinase BRAF, a downstream effector of the RAS oncogene along
the MEK/ERK signaling pathway, has emerged as an important biological marker for …
被引用次数：54 相关文章

BRAF mutation testing in clinical practice

J Ziai, P Hui - Expert review of molecular diagnostics, 2012 - pubmed.ncbi.nlm.nih.gov
Serine/threonine-protein kinase BRAF, a downstream effector of the RAS oncogene along
the MEK/ERK signaling pathway, has emerged as an important biological marker for …

BRAF mutation testing in clinical practice

J Ziai, P Hui - Expert Review of Molecular Diagnostics, 2012 - search.proquest.com
Serine/threonine-protein kinase BRAF, a downstream effector of the RAS oncogene along
the MEK/ERK signaling pathway, has emerged as an important biological marker for …

BRAF mutation testing in clinical practice

J Ziai, P Hui - Expert Review of Molecular Diagnostics, 2012 - go.gale.com
The involvement of RAF proteins in tumorigenesis has been studied for over 20 years.
Initially, interest in RAF mutations in human tumors stemmed from RAF proteins' â roles as …

BRAF mutation testing in clinical practice.

J Ziai, P Hui - Expert Review of Molecular Diagnostics, 2012 - europepmc.org
Serine/threonine-protein kinase BRAF, a downstream effector of the RAS oncogene along
the MEK/ERK signaling pathway, has emerged as an important biological marker for …